301230 泓博医药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)2.3383.3671.5893.3739.194
总资产报酬率 ROA (%)1.8082.6071.2192.6987.227
投入资产回报率 ROIC (%)1.9942.8421.3292.9257.847

边际利润分析
销售毛利率 (%)31.92127.41623.86430.87536.874
营业利润率 (%)15.3234.1580.6677.64615.211
息税前利润/营业总收入 (%)17.2565.0030.8307.38813.687
净利润/营业总收入 (%)13.8024.9823.1387.68214.028

收益指标分析
经营活动净收益/利润总额(%)48.451114.517-261.844107.78495.280
价值变动净收益/利润总额(%)70.38125.079237.82216.8900.691
营业外收支净额/利润总额(%)-1.593-1.074-2.769-1.8540.105

偿债能力分析
流动比率 (X)3.7603.3804.4203.8249.284
速动比率 (X)3.1692.9503.8703.5038.778
资产负债率 (%)21.72723.58021.55324.85414.476
带息债务/全部投入资本 (%)3.2683.5463.1393.3692.505
股东权益/带息债务 (%)2,623.7582,392.2972,675.3802,473.3903,608.381
股东权益/负债合计 (%)360.259324.082363.973302.350590.777
利息保障倍数 (X)7.9395.6274.595-61.885-8.885

营运能力分析
应收账款周转天数 (天)73.44664.23960.88961.59364.138
存货周转天数 (天)63.27251.55056.64959.82258.265